Food industry veteran Per Rehné is to join the board of OptioBiotix Health PLC (LON:OPTI) as commercial director.
Rehné will replace Jim Laird, who is leaving by mutual agreement.
The healthcare company, which is focused on tackling obesity, high cholesterol, diabetes and skin care, said Rehné’s experience of food, health, and nutrition markets will help drive commercialisation of OptiBiotix's growing pipeline of products and create multiple revenue streams across all technology platforms.
Until recently, he was European director of Health and Nutrition at Cornelius Group; under his leadership the division became the company's fastest growing business unit, quadrupling sales from a low base to double digit million pound revenues in less than three years.
He is a qualified food technologist and speaks English, Danish, German, Swedish and Norwegian.
"Per's experience and track record of growing business-to-business sales of ingredients and nutritional products brings operational commercial and industry expertise to OptiBiotix,” said Stephen O’Hara, chief executive officer of OptiBiotix.
“His network of contacts provides access to new international markets to help drive revenue growth from OptiBiotix's growing pipeline of products now entering their commercialisation phase; these include OptiBiotix's patented SlimBiome technology for hunger free weight loss and its LP-LDL probiotic strain for cholesterol and hypertension reduction.
“This is consistent with the overall aim of developing multiple revenue streams from both consumer and pharmaceutical products across all OptiBiotix's technology platforms,” O’Hara added.